Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 8, 22 | -0.53
Decreased by
-20.45%
|
-0.53 |
Aug 10, 22 | -0.56
Decreased by
-64.71%
|
-0.45
Decreased by
-24.44%
|
May 12, 22 | 0.10
Increased by
+112.20%
|
-0.18
Increased by
+155.56%
|
Mar 15, 22 | -0.47
Decreased by
-2.17%
|
-0.42
Decreased by
-11.90%
|
Nov 10, 21 | -0.44
Increased by
+84.51%
|
-0.44 |
Aug 12, 21 | -0.34
Increased by
+67.62%
|
-0.53
Increased by
+35.85%
|
May 17, 21 | -0.82
Increased by
+38.35%
|
-0.49
Decreased by
-67.35%
|
Mar 11, 21 | -0.46
Increased by
+91.68%
|
-0.88
Increased by
+47.73%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
-100.00%
|
-22.00 M
Decreased by
-56.97%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
-100.00%
|
-22.54 M
Decreased by
-107.65%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 24.99 M
Increased by
+727.73%
|
4.62 M
Increased by
+121.66%
|
Increased by
+18.48%
Decreased by
-96.55%
|
Dec 31, 21 | 6.02 M
Increased by
+11.28%
|
-15.81 M
Decreased by
-76.52%
|
Decreased by
-262.67%
Decreased by
-58.64%
|
Sep 30, 21 | 3.43 M
Increased by
+13.24%
|
-14.01 M
Increased by
+5.18%
|
Decreased by
-408.66%
Increased by
+16.27%
|
Jun 30, 21 | 4.81 M
Decreased by
-35.51%
|
-10.85 M
Decreased by
-28.37%
|
Decreased by
-225.47%
Decreased by
-99.07%
|
Mar 31, 21 | -3.98 M
Decreased by
-299.05%
|
-21.32 M
Decreased by
-375.23%
|
Increased by
+535.52%
Increased by
+338.75%
|
Dec 31, 20 | 5.41 M
Increased by
+174.76%
|
-8.96 M
Decreased by
-36.18%
|
Decreased by
-165.58%
Increased by
+50.44%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.